

Tillotts Pharma Transfers of Value in 2015 to Bulgarian Healthcare Professionals and Healthcare Organisations

Приложение № 2 - Формат на оповестяване по чл.13 от Кодекса за оповестяване на предоставяне на стойност

Date of publication: June 2016

Full Name Име/Наименование	HCPs: City of Principal Practice HCOs: city where registered Град, в който се упражнява дейността/МС/ седалище на ЗО	Country of Principal Practice Държава по регистрацията на практиката	Principal Practice Address Адрес на практиката	Donations and Grants to HCOs Дарения и спонсорство за ЗО	Contribution to costs of Events Разходи, свързани с участие в събития (чл. 18(1) т. 1.2 и чл.18 (2) т. 1.2.)			Fee for service and consultancy Плащания за услуги и консултации / Хонорари (чл.18 (1) , т. 1.3 и чл.18(2) ,т.2.2)		TOTAL ОБЩО
					Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event Договори за спонсорство със ЗО или с трети лица, посочени от ЗО като отговорни за провеждането на събитие	Registration Fees Такси за регистрацията	Travel & Accommodation Пътуване и настаняване	Fees Хонорари	Related expenses agreed in the contract, including travel & accommodation relevant to the contract Съпътстващи разходи за услугата, уговорени в консултантския договор	
(чл. 2)	(чл. 8)	чл. 8,9, 10, и 15	(чл. 3)	(чл.18 (1) т.1.1)						
INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate) ИНДИВИДУАЛНО ОПОВЕСТЯВАНЕ –отделен ред за всеки МС (т.е. всякакъв вид предоставяне на стойност на МС през годината ще бъде сумирана: детайлна информация ще бъде предоставена единствено и само на съответния медицински специалист или държавен орган при нужда)										
				N/A	N/A					
OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons ДРУГИ, (невключени по-горе поради правни ограничения, не позволяващи информацията да се оповести индивидуално)										
Aggregate amount attributable to transfers of value to such Recipients				N/A	N/A					
Обща сума на предоставената стойност на медицински специалисти - чл.19				N/A	N/A					
Number of Recipients in aggregate disclosure				N/A	N/A					
Брой медицински специалисти на обобщен принцип - чл.19				N/A	N/A					
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed				N/A	N/A					
% на броя Получатели, включени в обобщеното оповестяване, от общия брой на тези получатели - чл.19				N/A	N/A					

 HCPs
Медицински специалисти

HCOs Здравни организации	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate) Индивидуално, поименно оповестяване - отделен ред за ЗО (т.е. всички предоставяния на стойност за годината за отделна ЗО се сумират: подробности следва да са достъпни за отделния Получател или при поискване от оправомощени публични органи										
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons ДРУГИ (невключени по-горе поради правни ограничения, не позволяващи информацията да се оповести на индивидуална основа)										
	Aggregate amount attributable to transfers of value to such Recipients										
	Обща сума на предоставената стойност на здравни организации - чл.19										
	Number of Recipients in aggregate disclosure										
	Брой здравни организации на обобщен принцип - чл.19										
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed											
% на броя Получатели, включени в обобщеното оповестяване, от общия брой на тези получатели - чл.19											
R & D Научноизследователска и развойна дейност	AGGREGATE DISCLOSURE ОБОБЩЕНО ОПОВЕСТЯВАНЕ										
	Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1 Предоставяне на стойност за научноизследователска и развойна дейност (чл. 21)										CHF 128'926

Methodological Notes

Disclosure by Tillotts Pharma of payments to Bulgarian healthcare professionals and healthcare organisations in 2015

The Code for Disclosure of Transfers of Value of the Association of Research-based Pharmaceutical Manufacturers in Bulgaria (the ARPharM Code) mandates the public disclosure in 2016 of certain transfers of value made by pharmaceutical companies during 2015 to Bulgarian healthcare professionals and healthcare organisations. The disclosure data will be published on the website of Tillotts Pharma, www.tillotts.com.

The methodological notes below explain the data Tillotts Pharma have disclosed and how the data have been prepared, to assist the reader's understanding.

VAT

VAT is excluded from all disclosures of transfer of value.

Currency

All disclosures are made in Euros (€). Where the original payment was made in another currency, the sum was converted to Euros at the average annual exchange rate for 2015.

Consolidated Disclosures of the Corporate Group and Cross-border Payments

The disclosures represent the consolidated transfers of value made by the Tillotts Pharma corporate group in line with the EFPIA Disclosure Code's dictate that separate entities belonging to the same multinational company (which could be the parent company and subsidiary company) shall be deemed to constitute a single company. The disclosures for 2015 represent payments by Tillotts Pharma AG.

Multi-year contracts

Where multi-year contracts are included in the disclosure data, the disclosures related to such multi-year contracts represent the services rendered and paid for in calendar year 2015 under such contracts.

Data included

The data disclosed by Tillotts Pharma is consistent with the requirements of the ARPharM Code Code. The data can be categorised as follows:

Research & Development

Research & Development transfers of value are disclosed in the aggregate and encompass transfers of value to Bulgarian healthcare professionals and healthcare organisations related to a clinical trial in accordance with the Law on Medicinal Products for Human Use, as well as costs that are subsidiary to these activities.